All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 20 March 2018, the US Food and Drug Administration (FDA) granted approval of brentuximab vedotin in combination with chemotherapy, for the treatment of adults with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL).
The FDA approval was based on the successful results from the multicenter, open-label, randomized ECHELON-1 phase III clinical trial (NCT01712490). In this study, brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (A+AVD) was compared to AVD plus bleomycin (ABVD), as a regimen for advanced stage cHL patients. Superior efficacy of A+AVD was reported with a significantly lower combined risk of progression, as compared to ABVD.
The FDA had granted this application Priority Review and Breakthrough Therapy designation. According to Richard Pazdur, Director of the FDA Oncology Center of Excellence “Today’s approval represents an improvement in the initial treatment regimens of advanced HL that were introduced into clinical practice more than 40 years ago”.
In an interview we conducted at ASH 2017, Atlanta, GA, Professor Anas Younes from the Weill-Cornell Medical College, discussed the ECHELON-1 results and how they impact the current standard of care for advanced-stage HL patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox